233
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Diagnostics for Repurposed Drugs

      Preprint
      research-article
      This is not the latest version for this article. If you want to read the latest version, click here.
      Bookmark

            Abstract

            Precision Diagnostics is a prerequisite for Precision Medicine by enabling a characterization of diseases on a molecular level leading to mechanism-based treatment. Giving the right drug to the right patient at the right dose and at the right time requires novel biomarker signatures to stratify patients accordingly.

            Diagnostics play an essential role in the context of drug repurposing, where existing drugs are investigated and repurposed for a new therapeutic use. They are important to identify the eligible patient population for a repurposed drug. Diagnostics are extremely valuable in determining which patients are most likely to benefit from a specific treatment. This way the effectiveness of a drug or combination of drugs is significantly increased and the chance of potential adverse effects is reduced. In addition to precise diagnostics in the wet-lab, both the patient recruitment and avoidance of adverse events can currently be supported by artificial intelligence (AI) based on empirical data sets (Cai, T. et al., 2021, Syrowatka, A. et al., 2022).

            Content

            Author and article information

            Journal
            DrugRxiv
            REPO4EU
            22 February 2024
            Affiliations
            [1 ] GeneSurge, Germany;
            [2 ] Department of Pharmacology & Personalised Medicine, Faculty of Health, Medicine & Life Science, Maastricht University, Netherlands;
            [3 ] BioLizard, Belgium;
            [4 ] Sciomics, Germany;
            [5 ] Department of Pharmacology & Personalised Medicine, Faculty of Health, Medicine & Life Science, Maastricht University, Netherlands ( https://ror.org/02jz4aj89)
            Author notes
            Author information
            https://orcid.org/0000-0001-7535-0417
            https://orcid.org/0000-0002-5907-3779
            Article
            10.58647/DRUGARXIV.PR000006.v1
            e09aaedb-d0c9-4ab0-b30d-7be92e84d3f2

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            History
            : 22 February 2024
            Funding
            Funded by: funder-id http://dx.doi.org/10.13039/100018696, HORIZON EUROPE Health;
            Award ID: 101057619
            Categories

            All data generated or analysed during this study are included in this published article (and its supplementary information files).
            Molecular medicine,Molecular biology,Bioinformatics & Computational biology,Pharmacology & Pharmaceutical medicine
            diagnostics,biomarker,repurposed drugs,artificial intelligence,multi-omics,mechanism-based

            Comments

            Comment on this article